Video 6

Movie S6. An advanced PyMT/c-fms-EGFP/ACTB-ECFP tumor from a mouse pretreated with M279 for 3 wk, starting at 9 wk of age, and then treated with a combination of M279 and doxorubicin chemotherapy for further 3 wk. The last doxorubicin dose was given 25 h before imaging was started, and Alexa Fluor 647-labeled Gr-1 antibody (red) was injected intravenously 1 h before imaging. Propidium iodide (white) was administered intraperitoneally every hour during imaging. Tumor cells are seen in blue, c-fms-EGFP+ myeloid cells in green. Note the highly motile Gr-1+ EGFP+ neutrophils accumulating in the tumor, as doxorubicin-induced cell death increases.